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revealed a cost of US $1438 compared to $1074 and $888 for simple excision and 
ED& C respectively. Sensitivity analysis using probability of recurrence had little 
impact on the base case cost modeling with imiquimod falling between ED & C and 
simple excision. CONCLUSIONS: The overall cost of therapy of sBCC by topical 
imiquimod was slightly higher compared to the common ofﬁce-based surgical treat-
ments. Preferences for number of visits, cosmetic outcome, risks of surgery, side effects 
of topical treatment all need to be considered on an individual basis.
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OBJECTIVES: The second line options for patients with GIST on imanitib 400 mg/ 
day, whose tumor continued to progress is: imatinib dose increased to 600 mg/day 
followed by another increase to 800 mg/day. In case of intolerance, only palliative 
treatment was available. In these cases, TTP was not higher than 6.4 weeks. Sunitinib 
malate consists of a new therapeutic alternative for this unmet medical need. The 
objective of this economic evaluation was to estimate the costs and outcomes for GIST 
treatment with sunitinib, compared with best supportive care (BSC) and imatinib 
800 mg/day, under the Brazilian public health care system perspective METHODS: A 
Markov model was developed, with a maximum of 6 years time horizon, to simulate 
the costs and outcomes associated to GIST treatment, considering health care resources 
from the Brazilian Public Health Care System perspective (SUS). The model considers 
disease progression, death from all causes, adverse events and dose decrease needs 
every 6 weeks cycles. Results were expressed as life-years (LY) gained, progression-free 
LY (PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) 
RESULTS: In comparison with BSC, sunitinib increases LY and PFLY by 0.3 and 
0.26 years respectively, with incremental costs of R$86,756 (US$61,968 Purchasing 
Power Parity 2005, 1US$  1,4R$) In comparison with imatininb, sunitinib was both 
more effective (with 0.02 LY and 0.47 PFLY gained) and less costly over 6 years. 
CONCLUSIONS: This model suggests that when taking the perspective of the Brazil-
ian Public Health Care System (SUS), sunitinib is a cost-effective alternative when 
compared with imatinib 800 mg/day in a 6 years time horizon. In comparison to BSC, 
sunitinib promoted better results on efﬁcacy parameters, with an incremental cost in 
the same time horizon.
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OBJECTIVES: To assess the incremental cost effectiveness ratio (ICER) of Clofarabine 
for the treatment of pediatric patients 1 to 21 years old with refractory or relapsed 
acute leukemias compared against the usual care in this patient group. METHODS: 
A decision tree model of the outcomes of Clofarabine compared against the usual care 
was constructed to estimate the cost-effectiveness of a hypothetical cohort of pediatric 
patients 1 to 21 years old with refractory or relapsed acute leukemia. The results of 
clinical trail (CLO 212) were used to create a model of disease progression and treat-
ment patterns. The analysis was performed from the Mexican Health Care System 
perspective, only direct costs were considered and all costs were reported in 2008 
Mexican pesos. Extensive sensitivity and variability analyses were performed to test 
the robustness of the cost-effectiveness results. RESULTS: Life expectancy was greater 
for clofarabine than usual supportive care; 3.04 and 0.37 years, respectively. Total 
lifetime medical cost was US$63,938 for clofarabine and US$6,475 for best supportive 
care. The incremental cost-effectiveness of clofarabine was US$21,528 per life year 
gained. Considering a willingness to pay (WTP) threshold of S21,800 “3 GDP” per 
LY, there is a 90% probability that treatment with clofarabine is cost-effective relative 
to best supportive care treatment. Sensitivity analyses showed that drug cost acquisi-
tion, age, discount rate most affected estimates of cost-effectiveness CONCLUSIONS: 
We estimated the ICER for clofarabine compared to usual care at approximately $ 
21,528 per life year gained in the treatment of acute lymphoblastic leukemia in 
Mexico. This ratio may well be in range of what is acceptable and warrants reimburse-
ment for new drug treatments in the Mexico, in particular in therapeutic areas as 
end-stage oncology and HIV and other last-resort health care interventions.
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OBJECTIVES: To assess cost effectiveness of Letrozole vs Tamoxifen in ﬁve-year 
adjuvant treatment of hormone receptor-positive, post-menopausal early breast cancer 
patients in Colombia. METHODS: The natural history of the disease and the effects 
of treatment were modeled as a Markov process. Effectiveness was deﬁned as disease-
free survival. Transition probabilities for the disease and adverse effects were obtained 
from the literature. Costs are the median of actual costs for some health insuring ﬁrms 
and the National Cancer Institute, and are expressed in 2007 Colombian pesos (COP). 
Sensibility analysis were also carried out for costs, effectiveness, discount and model 
assumptions. RESULTS: Compared to Tamoxifen, Letrozole results in an additional 
relapse-free period of 0.45 years. Each year obtained in this way costs $58,128,304 
(COP), or $79,355,466 (COP) with a discount rate of 3%. The results were not sensi-
tive to relapse cost, adverse events and discount. Drug cost was the main variable that 
affected cost effectiveness: Letrozole is cost effectiveness for Colombia if its cost is 
lower than $2081 (COP) per tablet. CONCLUSIONS: The use of Letrozole has an 
additional cost per relapse-free year over the Colombian per capita GDP ($7,521,363 
(COP) in 2007). Hence, for postmenopausal, early breast cancer hormone receptor 
positive women in Colombia, the cost-effective alternative is Tamoxifen as adjunvant 
therapy for ﬁve years.
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OBJECTIVOS: Determinar si en pacientes aﬁliadas al sistema de salud colombiano 
que asisten al Instituto Nacional de Cancerología, con cáncer de mama temprano y 
sobreexpresión del marcador Her2-neu, es costo efectivo el uso de trastuzumab como 
terapia adyuvante, desde el punto de vista del pagador. METODOLOGÍAS: Se realizó 
un estudio de costo-efectividad empleando un modelo de Markov, con la perspectiva 
del pagador, horizonte de tiempo la expectativa de vida de las mujeres colombianas 
y tasa de descuento 3%. Se construyó un modelo de historia natural de la enfermedad, 
se establecieron los costos para los diferentes escenarios usando el manual tarifario 
SOAT del Ministerio de la Protección Social, para el año 2008. RESULTADOS: El 
costo del tratamiento adyuvante sin trastuzumab es $9,396,220. El costo del trata-
miento adyuvante con Trastuzumab es $126,380,645. El costo de la ICC aguda 
inducida por trastuzumab es $2,252,600 y la ICC crónica $863,520. El uso de trastu-
zumab adyuvante durante un año, produce una relación de costo efectividad de 
$39,516,226 sin descuento y $58,090,827 con descuento por cada año de vida 
ganado. El análisis de sensibilidad muestra una relación costo efectividad favorable si 
se usa por periodos menores a un año, siempre y cuando se mantenga lae efectividad 
y el paciente logre vivir por lo menos diez años. CONCLUSIONES: Trastuzumab es 
un medicamento de efectividad comprobada en la terapia adyuvante, en Colombia el 
costo de un año de tratamiento adyuvante contrasta con el PIB percapita de US$3729, 
este estudio sugiere que para una mayor eﬁciencia de los medicamentos innovadores 
estos deben tener costos que permitan su acceso en los países de ingresos bajos, por 
tanto se sugiere el aprobación de nuevo medicamentos con precios preferenciales para 
estos países.
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OBJECTIVES: To compare the cost-effectiveness of Palonosetron in the Prevention 
of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Highly 
Emetogenic Chemotherapy METHODS: A decision analytic model was used to syn-
thesise the health care costs and beneﬁt of a Palonosetron regimen versus Ondansetron 
over a ﬁve days period. The main effectiveness measure was “complete response CR”, 
deﬁned as the percentage of patients who had neither emesis nor rescue therapy over 
the 5-day cycle, was derived from a previously published clinical trial. Uncertainty in 
the data parameters was investigated through a series of one-way sensitivity analyses, 
simulation methods and scenario analyses. The analysis was conducted from the 
Mexican health care perspective using 2008 unit cost prices RESULTS: The corre-
sponding health effects were 0.69 CR for Palonosetron and 0.48 CR for Ondansetron 
regimen. The mean total cost of the Palonosetron regimen was US$77.45 compared 
with $US 58.09 for the Ondansetron regimen. The cost of successfully treating one 
patient with Palonosetron and Ondansetron was US$94.18.87 and US$111.73, respec-
tively. The incremental cost-effectiveness ratio was $US 94.18 per CR gained for 
Palonosetron over the 5-day period. Findings were robust across various sensitivity 
analyses CONCLUSIONS: The results indicate that Palonosetron is a more cost-
 effective antiemetic compared with Ondansetron for the prevention of CINV associ-
ated with highly emetogenic chemotherapy. The incidence of CINV and use of rescue 
antiemetics was signiﬁcantly greater in the Ondansetron group compared with the 
Palonosetron group.
